American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 370-372 , March 2009

New Approaches For Desensitization Strategies Prior to Kidney Transplantation

  • Monica Grafals, MD
    • ,
  • Anil Chandraker, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Anil Chandraker, MD, Renal Division & Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, 75 Francis St, Boston, MA 02115

References 

  1. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339–1343
  2. Waterman AD, Schenk EA, Barrett AC, et al. Incompatible kidney donor candidates' willingness to participate in donor-exchange and non-directed donation. Am J Transplant. 2006;6:1631–1638
  3. Organ Procurement Transplantation Network/Scientific Registry of Transplant Recipients. 2004 Annual Report: Transplant Data 1994-2003. Rockville, MD, Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; Richmond, VA, United Network of Organ Sharing; Ann Arbor, MI, University Renal Research and Education Association 2004;
  4. Beimler JH, Susal C, Zeir M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant. 2006;20(suppl 17):7–12
  5. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3:653–664
  6. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251
  7. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized patients with end-stage renal disease: report of the NIH IGO2 trial. J Am Soc Nephrol. 2004;15:3256–3262
  8. Jordan SC, Quartel AW, Czer LS, et al. Post-transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action. Transplantation. 1994;57:553–562
  9. Montgomery RA, Zachary AA, Racuse LC, et al. Plasmapheresis and intravenous immunoglobulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation. 2000;70:887–895
  10. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant. 2008;8:144–149
  11. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2:758–760
  12. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol. 2008;3:1160–1167

PII: S0272-6386(09)00043-2

doi: 10.1053/j.ajkd.2009.01.012

American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 370-372 , March 2009

Article Tools